Transduction for AAV with Sean Hart

June 13, 2023

News

Video

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured. The full discussion can and more can be viewed here.

Related Content

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol

March 25th 2025

Article

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Magnified View of Lipid Nanoparticles | Image Credit: ©Aniwat - stock.adobe.com

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

Cynthia A. Challener

March 9th 2025

Article

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.

Drug Solutions Podcast: The Biosimilars Landscape

Feliza Mirasol

January 31st 2024

Podcast

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.